Viropro Inc. (OTCPK:VPRO) signed a non-binding letter of intent to acquire Therapix Biosciences Ltd. (TASE:TRPX) from a group of investors on December 4, 2013. The investors are The Pontifax Fund, fund of Pontifax Ltd., IBI Mutual Funds Management Ltd., Gilbood Trading S.A, Quantum Technology Management Company IV, LLC and other shareholders. As per the terms of the transaction, Viropro will directly or indirectly own all of the Therapix assets, rights, and liabilities.

Therapix's Chief Executive Officer, Ari Aminetzah will be the Chief Executive Officer of the merged company and Viropro's President and Chief Executive Officer, Cynthia Ekberg Tsai will become Chief Executive Officer for Business Development. The transaction is subject to several conditions, including completion of due diligence by Viropro and Therapix, execution of necessary documents, approval by the Directors and shareholders and compliance with applicable regulatory agencies.